Sansure Biotech (688289.SS) Stock Price

Sansure Biotech Price

SSE·CLOSED
16.82CNY+1.26 (+7.78 %)
Market closed

Over the last 7 years Sansure Biotech grew revenue by 30.6% annually, reaching 1.46 B CNY. Earnings per share have grown at 43.8% per year over the last 6 years. For Sansure Biotech, the net margin of 18.9% is down versus 54.9% a few years ago. At today's price the dividend yield works out to roughly 2.68%. The payout ratio is around 96% of earnings. The consensus 12-month price target for Sansure Biotech is 26.42 CNY, about 57.1% above where the stock trades today. Of 7 analysts, 6 rate the stock a buy — an overall Buy consensus. The stock trades about 25% above its 52-week low.

Sansure Biotech stock price

Volume
Ex-Dividend
Details

Stock Price

ⓘ

How to Read This Chart

This chart tracks the historical stock price of Sansure Biotech over time. You can switch between daily, weekly, and monthly views and select custom time ranges — from a single day to the full available history. Use the toggle to view price changes in absolute currency terms or as a percentage change relative to the starting date.

Total Return vs. Price Return

The "Total Return" toggle includes reinvested dividends on top of the pure price movement. This is critical because dividends can account for a significant portion of long-term returns. Historically, roughly 40 % of the S&P 500's total return has come from dividends. Always compare total return when evaluating a stock's real performance against a benchmark.

Intraday Price Data

When viewing a one-day time frame, the chart displays real-time intraday price movements. This is useful for observing how Sansure Biotech stock reacts to market openings, earnings releases, or breaking news throughout the trading session.

What to Look For

Look for long-term trends (sustained upward or downward movements over months and years), support and resistance levels (price zones where the stock repeatedly bounces or reverses), and volatility (how much the price fluctuates day to day). Comparing Sansure Biotech's price chart to a market index like the S&P 500 can reveal whether the stock is outperforming or underperforming the broader market.

Sansure Biotech Stock Price History
DateSansure Biotech Price
8/13/202616.82 CNY
8/12/202615.56 CNY
8/11/202615.62 CNY
8/10/202615.76 CNY
8/7/202615.71 CNY
8/6/202615.32 CNY
8/5/202615.45 CNY
8/4/202615.49 CNY
8/3/202615.68 CNY
7/31/202615.44 CNY
7/30/202615.34 CNY
7/29/202615.19 CNY
7/28/202614.84 CNY
7/27/202614.91 CNY
7/24/202614.56 CNY
7/23/202614.78 CNY
7/22/202615.03 CNY
7/21/202615.39 CNY
7/20/202615.67 CNY
7/17/202615.44 CNY
7/16/202615.91 CNY
7/15/202615.83 CNY
7/14/202615.25 CNY
7/13/202615.13 CNY
7/10/202614.99 CNY
7/9/202614.67 CNY
7/8/202614.60 CNY
7/7/202614.54 CNY
7/6/202615.13 CNY
7/3/202615.16 CNY
7/2/202615.05 CNY
7/1/202615.28 CNY
6/30/202614.40 CNY
6/29/202614.70 CNY
6/26/202614.12 CNY
6/25/202613.87 CNY
6/24/202614.27 CNY
6/23/202614.17 CNY
6/22/202613.46 CNY
6/18/202614.36 CNY
6/17/202614.19 CNY
6/16/202614.27 CNY
6/15/202614.30 CNY
6/12/202614.21 CNY
6/11/202614.19 CNY
6/10/202614.66 CNY
6/9/202614.86 CNY
6/8/202615.05 CNY
6/5/202615.55 CNY
6/4/202615.36 CNY
6/3/202615.70 CNY
6/2/202616.22 CNY
6/1/202616.66 CNY
5/29/202616.32 CNY
5/28/202616.20 CNY
5/27/202616.75 CNY
5/26/202617.52 CNY
5/25/202617.53 CNY
5/22/202617.38 CNY
5/21/202617.50 CNY
5/20/202617.57 CNY
5/19/202617.57 CNY
5/18/202617.48 CNY
5/15/202617.45 CNY
5/14/202617.69 CNY
5/13/202618.08 CNY
5/12/202618.25 CNY
5/11/202619.06 CNY
5/8/202618.12 CNY
5/7/202617.46 CNY
5/6/202617.21 CNY
4/30/202617.15 CNY
4/29/202617.42 CNY
4/28/202617.24 CNY
4/27/202617.13 CNY
4/24/202617.44 CNY
4/23/202617.66 CNY
4/22/202617.88 CNY
4/21/202617.86 CNY
4/20/202617.94 CNY
4/17/202617.90 CNY
4/16/202618.22 CNY
4/15/202618.26 CNY
4/14/202618.29 CNY
4/13/202618.09 CNY
4/10/202618.31 CNY
4/9/202618.22 CNY
4/8/202618.47 CNY
4/7/202618.12 CNY
4/3/202617.76 CNY
4/2/202618.24 CNY
4/1/202618.46 CNY
3/31/202618.06 CNY
3/30/202618.01 CNY
3/27/202618.28 CNY
3/26/202617.87 CNY
3/25/202618.26 CNY
3/24/202618.29 CNY
3/23/202618.03 CNY
3/20/202618.58 CNY
3/19/202618.85 CNY
3/18/202619.08 CNY
3/17/202618.93 CNY
3/16/202618.93 CNY
3/13/202618.28 CNY
3/12/202618.21 CNY
3/11/202618.32 CNY
3/10/202618.52 CNY
3/9/202618.41 CNY
3/6/202618.34 CNY
3/5/202618.09 CNY
2/27/202619.21 CNY
2/26/202619.19 CNY
2/25/202619.49 CNY
2/13/202619.33 CNY
2/12/202619.58 CNY
2/11/202619.83 CNY
2/10/202620.00 CNY
2/9/202620.04 CNY
2/6/202620.00 CNY
2/5/202620.00 CNY
2/4/202620.00 CNY
2/3/202620.01 CNY
2/2/202619.86 CNY
1/30/202620.28 CNY
1/29/202620.27 CNY
1/28/202620.66 CNY
1/27/202622.12 CNY
1/26/202621.99 CNY
1/23/202620.17 CNY
1/22/202619.85 CNY
1/21/202619.82 CNY
1/20/202619.75 CNY
1/19/202619.89 CNY
1/16/202619.93 CNY
1/15/202620.16 CNY
1/14/202620.49 CNY
1/13/202620.69 CNY
1/12/202620.66 CNY
1/9/202620.13 CNY
1/8/202619.48 CNY
1/7/202619.33 CNY
1/6/202619.48 CNY
1/5/202619.35 CNY
12/31/202518.88 CNY
12/30/202518.90 CNY
12/29/202519.00 CNY
12/26/202519.14 CNY
12/25/202519.16 CNY
12/24/202519.13 CNY
12/23/202519.10 CNY
12/22/202519.10 CNY
12/19/202519.17 CNY
12/18/202519.11 CNY
12/17/202518.67 CNY
12/15/202518.88 CNY
12/12/202518.70 CNY
12/11/202518.86 CNY
12/10/202519.05 CNY
12/9/202519.12 CNY
12/8/202519.70 CNY
12/5/202520.06 CNY
12/4/202519.89 CNY
12/3/202520.19 CNY
12/2/202520.30 CNY
12/1/202520.35 CNY
11/28/202520.27 CNY
11/27/202520.20 CNY
11/26/202520.20 CNY
11/25/202520.13 CNY
11/24/202519.93 CNY
11/21/202519.85 CNY
11/20/202520.50 CNY
11/19/202520.71 CNY
11/18/202520.88 CNY
11/17/202521.22 CNY
11/14/202521.91 CNY
11/13/202521.78 CNY
11/12/202521.93 CNY
11/11/202521.81 CNY
11/10/202521.95 CNY
11/7/202521.77 CNY
11/6/202521.70 CNY
11/5/202522.03 CNY
11/4/202522.00 CNY
11/3/202521.97 CNY
10/31/202522.05 CNY
10/30/202521.57 CNY
10/29/202521.78 CNY
10/28/202521.54 CNY
10/27/202521.89 CNY
10/24/202522.10 CNY
10/23/202522.06 CNY
10/22/202522.03 CNY
10/21/202520.31 CNY
10/20/202520.16 CNY
10/17/202520.19 CNY
10/16/202520.74 CNY
10/15/202520.99 CNY
10/14/202521.00 CNY
10/13/202521.19 CNY
10/10/202521.36 CNY
10/9/202521.37 CNY
9/30/202521.19 CNY
9/29/202520.52 CNY
9/26/202520.50 CNY
9/25/202519.89 CNY
9/24/202520.05 CNY
9/23/202519.65 CNY
9/22/202520.28 CNY
9/19/202520.24 CNY
9/18/202520.25 CNY
9/17/202520.67 CNY
9/16/202520.62 CNY
9/15/202520.57 CNY
9/12/202520.57 CNY
9/11/202520.58 CNY
9/10/202520.35 CNY
9/9/202520.45 CNY
9/8/202520.82 CNY
9/5/202520.42 CNY
9/4/202520.15 CNY
9/3/202520.40 CNY
9/2/202520.83 CNY
9/1/202521.34 CNY
8/29/202521.11 CNY
8/28/202521.40 CNY
8/27/202521.67 CNY
8/26/202522.27 CNY
8/25/202522.30 CNY
8/22/202522.24 CNY
8/21/202522.08 CNY
8/20/202521.94 CNY
8/19/202521.88 CNY
8/18/202522.07 CNY
8/15/202521.82 CNY
Access this data via the Eulerpool API
Get Free API Key

Sansure Biotech Revenue, EBIT, Net Income

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue
EBIT
Net Income
Details
Date
Revenue
EBIT
Net Income
Jan 1, 2021
4.51 B CNY
2.55 B CNY
2.24 B CNY
Jan 1, 2022
6.45 B CNY
2.23 B CNY
1.94 B CNY
Jan 1, 2023
1.01 B CNY
55.55 M CNY
363.72 M CNY
Jan 1, 2024
1.46 B CNY
215.85 M CNY
275.60 M CNY
Jan 1, 2025 (e)
1.66 B CNY
554.26 M CNY
219.89 M CNY
Jan 1, 2026 (e)
1.82 B CNY
607.11 M CNY
250.68 M CNY
Jan 1, 2027 (e)
2.07 B CNY
690.90 M CNY
307.85 M CNY
Jan 1, 2028 (e)
2.31 B CNY
768.96 M CNY
338.14 M CNY

Sansure Biotech Income Statement, Balance Sheet, Cash Flow Statement

Last updated Aug 15, 2026, 7:15 AM
 
REVENUEB CNY
REVENUE GROWTH%
GROSS MARGIN%
GROSS INCOMEB CNY
EBITB CNY
EBIT MARGIN%
NET INCOMEB CNY
NET INCOME GROWTH%
DIV.CNY
DIV. GROWTH%
SHARESM
201720182019202020212022202320242025e2026e2027e2028e
0.220.300.374.764.516.451.011.461.661.822.072.31
–35.2720.461,204.93-5.2342.89-84.3944.7914.139.5013.8311.28
49.5558.4265.2179.6371.6754.9172.1981.0081.0081.0081.0081.00
0.110.180.243.793.243.540.731.181.351.481.681.87
-0.020.010.053.092.552.230.060.220.550.610.690.77
-7.592.9712.3364.9456.4534.515.4614.7533.2933.3233.2733.28
-0.010.010.042.622.241.940.360.280.220.250.310.34
–-160.00550.006,607.69-14.30-13.65-81.25-24.24-20.3614.1622.8010.10
––––1.522.47–0.450.540.640.76–
–––––62.50––20.0018.5218.75–
127.90127.90358.20373.30591.65585.14586.65586.37586.37586.37586.37586.37
Details

Income Statement Key Figures

ⓘ

Revenue and Revenue Growth

Revenue is the starting point of every income statement — it measures the total sales Sansure Biotech generates from its core business. Revenue growth (expressed as year-over-year percentage change) is one of the most important indicators of business momentum. Sustained growth above 10 % annually is generally considered strong, while declining revenue is a serious warning sign that demands investigation.

Gross Margin

Gross margin = (Revenue − Cost of Goods Sold) ÷ Revenue. It reveals what percentage of each dollar of revenue Sansure Biotech retains after direct production costs. High gross margins (above 50 %) are typical of asset-light businesses like software and brands, while capital-intensive industries like manufacturing often operate below 30 %. Compare Sansure Biotech's gross margin to industry peers and track it over time to spot improving or deteriorating pricing power.

EBIT and EBIT Margin

EBIT measures operating profit — what remains after subtracting all operating expenses (including R&D, sales, and administrative costs) from gross profit. The EBIT margin shows this as a percentage of revenue. Because it excludes interest and taxes, EBIT allows fair comparisons between companies with different debt levels and tax jurisdictions. A rising EBIT margin indicates improving operational efficiency.

Net Income and Earnings Per Share (EPS)

Net income is the company's final profit after all expenses, interest, and taxes. Dividing net income by the number of shares outstanding gives you EPS — the single most influential metric in stock valuation. Consistent EPS growth is the primary driver of long-term stock price appreciation. Always check whether EPS growth comes from genuine profit improvement or from share buybacks reducing the share count.

Shares Outstanding

The total number of shares Sansure Biotech has issued. A declining share count (through buybacks) boosts EPS and signals management confidence. A rising share count (through stock issuance) dilutes existing shareholders. Always monitor this number alongside EPS to get the full picture of per-share value creation.

Analyst Estimates

The projected figures represent consensus estimates from professional analysts. Compare these forecasts against Sansure Biotech's historical growth rates to assess whether expectations are realistic. A company that consistently beats consensus estimates tends to see its stock price rewarded over time, while repeated misses erode investor confidence.

Sansure Biotech stock margins

The Sansure Biotech margin analysis displays the gross margin, EBIT margin, as well as the profit margin of Sansure Biotech. The EBIT margin (EBIT/sales) indicates the percentage of sales that remains as operating profit. The profit margin shows the percentage of sales that remains for Sansure Biotech.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Gross margin
EBIT margin
Profit margin
Details
Date
Gross margin
EBIT margin
Profit margin
Jan 1, 2020
79.63 %
64.94 %
54.94 %
Jan 1, 2021
71.67 %
56.45 %
49.68 %
Jan 1, 2022
54.92 %
34.51 %
30.03 %
Jan 1, 2023
72.28 %
5.52 %
36.12 %
Jan 1, 2024
81.00 %
14.80 %
18.90 %
Jan 1, 2025 (e)
81.00 %
33.30 %
13.21 %
Jan 1, 2026 (e)
81.00 %
33.30 %
13.75 %
Jan 1, 2027 (e)
81.00 %
33.30 %
14.84 %

Sansure Biotech Stock Revenue, EBIT, Earnings per Share

The Sansure Biotech earnings per share therefore indicates how much revenue Sansure Biotech has generated per share in a given period. The earnings before interest and taxes per share shows how much of the operating profit corresponds to each share. The earnings per share indicates how much of the profit belongs to each share.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Revenue per Share
EBIT per share
Earnings per Share
Details
Date
Revenue per Share
EBIT per share
Earnings per Share
Jan 1, 2020
12.76 CNY
8.29 CNY
7.01 CNY
Jan 1, 2021
7.63 CNY
4.31 CNY
3.79 CNY
Jan 1, 2022
11.02 CNY
3.80 CNY
3.31 CNY
Jan 1, 2023
1.72 CNY
0.09 CNY
0.62 CNY
Jan 1, 2024
2.49 CNY
0.37 CNY
0.47 CNY
Jan 1, 2025 (e)
2.84 CNY
0.95 CNY
0.38 CNY
Jan 1, 2026 (e)
3.11 CNY
1.04 CNY
0.43 CNY
Jan 1, 2027 (e)
3.54 CNY
1.18 CNY
0.53 CNY

Sansure Biotech business model & stock analysis

Sansure Biotech Eulerpool Fair Value

Details

Fair Value Estimate

ⓘ

What Is Fair Value?

Fair value is an estimate of what a stock is truly "worth" based on its financial fundamentals, independent of the current market price. If the calculated fair value is above the current share price, the stock may be undervalued — and vice versa. This chart shows three different fair value approaches so you can cross-check them against each other.

Earnings-Based Fair Value

Calculated by multiplying the current earnings per share (EPS) by the average historical P/E ratio over a selected multi-year period. The smoothing over several years filters out temporary spikes or dips. If this fair value exceeds the market price, it suggests the stock is cheap relative to its earning power.

Example: Fair Value (Earnings) 2022 = EPS 2022 × Average P/E 2019–2021

Revenue-Based Fair Value

Derived by multiplying revenue per share by the average historical price-to-sales ratio. This method is particularly useful for companies with volatile or temporarily depressed earnings, as revenue tends to be more stable than profits. It answers: "At what price has the market historically valued each dollar of this company's sales?"

Example: Fair Value (Revenue) 2022 = Revenue per Share 2022 × Average P/S 2019–2021

Dividend-Based Fair Value

Calculated by dividing the dividend per share by the average historical dividend yield. This approach is most relevant for mature, consistently dividend-paying companies. If the resulting fair value is higher than the current price, it implies the stock offers a better yield than its historical average.

Example: Fair Value (Dividend) 2022 = Dividend per Share 2022 ÷ Average Yield 2019–2021

How to Use This Chart

When all three fair value lines converge above the current price, it strengthens the case that the stock is undervalued. When they diverge, investigate why — it may indicate a structural shift in margins, payout policy, or growth rate. The forward estimates on the right extend the analysis using projected fundamentals, helping you assess whether the current price already reflects future growth expectations.

Sansure Biotech historical P/E ratio, EBIT multiple, and P/S ratio

Sansure Biotech annual returns

Details

Annual Return

ⓘ

What This Chart Shows

This chart breaks down 's total annual return into two components: price return (gains or losses from stock price movement) and dividend return (income received from dividend payments). Together, they represent the total return an investor would have earned in each calendar year.

Price Return

Price return measures the percentage change in 's stock price from January 1st to December 31st of each year. Positive bars indicate the stock appreciated; negative bars show a decline. This is the component most investors focus on, but it tells only part of the story — especially for dividend-paying stocks.

Dividend Return

Dividend return represents the income generated from dividends paid during the year, expressed as a percentage of the starting stock price. While it may seem small in any single year (typically 1–4 % for established companies), dividends compound significantly over decades and have historically contributed roughly 40 % of total stock market returns.

What to Look For

Examine how many years showed positive vs. negative returns to gauge consistency. A stock with mostly positive years and small drawdowns suggests lower risk. Also compare 's annual returns to a benchmark index — consistently outperforming the market is a hallmark of a strong investment. Pay attention to the worst years: understanding downside risk is just as important as chasing upside potential.

Sansure Biotech shares outstanding

The number of shares of Sansure Biotech was 586.37 M in 2025. This indicates how many shares Sansure Biotech is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Number of stocks
Details
Date
Number of stocks
Jan 1, 2020
373.30 M Stocks
Jan 1, 2021
591.65 M Stocks
Jan 1, 2022
585.14 M Stocks
Jan 1, 2023
586.65 M Stocks
Jan 1, 2024
586.37 M Stocks
Jan 1, 2025 (e)
586.37 M Stocks
Jan 1, 2026 (e)
586.37 M Stocks
Jan 1, 2027 (e)
586.37 M Stocks

Sansure Biotech stock splits

In Sansure Biotech's history, there have been no stock splits.

Sansure Biotech Dividend History

7 years of dividend payments

YearAnnual DividendYoY ChangePayments
20260.26CNYYTD—1×
Jun 22, 20260.26CNY↓ 0.4%1/1
20250.54CNY↑ 19.3%2×
Jun 11, 20250.28CNY↑ 10.0%1/2
Sep 23, 20250.26CNY↓ 4.7%2/2
20240.45CNY↓ 35.6%2×
20230.70CNY↓ 37.3%2×
20221.11CNY↓ 0.9%2×
20211.13CNY↑ 50.0%2×
20200.75CNY—1×

Sansure Biotech dividend history and estimates

In 2025, Sansure Biotech paid a dividend amounting to 0.54 CNY. Dividend means that Sansure Biotech distributes a portion of its profits to its owners.

  • Max

Dividend
Dividend (Estimate)
Special dividend
Details
Date
Dividend
Dividend (Estimate)
Special dividend
Jan 1, 2020 (e)
0.75 CNY
0.00 CNY
0.00 CNY
Jan 1, 2021 (e)
1.13 CNY
0.40 CNY
0.00 CNY
Jan 1, 2022 (e)
1.11 CNY
1.36 CNY
0.00 CNY
Jan 1, 2023 (e)
0.70 CNY
0.00 CNY
0.51 CNY
Jan 1, 2024
0.45 CNY
0.00 CNY
0.51 CNY
Jan 1, 2025
0.54 CNY
0.00 CNY
0.00 CNY
Jan 1, 2026 (e)
0.00 CNY
0.64 CNY
0.70 CNY
Jan 1, 2027 (e)
0.00 CNY
0.76 CNY
0.20 CNY

Sansure Biotech dividend payout ratio

In 2025, Sansure Biotech had a payout ratio of 143.20%. The payout ratio indicates the percentage of the company's profits that Sansure Biotech distributes as dividends.

  • 3 Years

  • 5 Years

  • 10 Years

  • 25 Years

  • Max

Payout ratio
Details
Date
Payout ratio
Jan 1, 2020
7.23 %
Jan 1, 2021
20.05 %
Jan 1, 2022
37.34 %
Jan 1, 2023
112.77 %
Jan 1, 2024
95.74 %
Jan 1, 2025 (e)
143.20 %
Jan 1, 2026 (e)
149.90 %
Jan 1, 2027 (e)
145.66 %

Current Sansure Biotech forecasts and price targets in August 2026

Analyst Price Targets 2026
Δ MOM Price Target
0.00 %
Buy
85.71 % (6)
Hold
14.29 % (1)
Sell
0.00 % (0)
12M Price Target
26.42
Last Price
16.82
Currency
CNY
12M Return Potential
57.06 %
LTM Return
0 %

EESG©

Eulerpool ESG Scorecard© for the Sansure Biotech stock

66/100
99
Environment
78
Social
21
Governance
E

Environment

20
Scope 1 - Direct Emissions128.34
Scope 2 - Indirect emissions from purchased energy6,933.59
Scope 3 - Indirect emissions within the value chain—
Total CO₂ emissions7,061.93
CO₂ reduction strategy
Coal energy
Nuclear power
Animal experiments
Fur & Leather—
Pesticides—
Palm Oil—
Tobacco
Genetically modified organisms
Climate concept—
Sustainable forestry—
Recycling regulations
Environmentally friendly packaging
Hazardous substances
Fuel consumption and efficiency
Water consumption and efficiency
S

Social

20
Percentage of female employees49.446
Percentage of women in management—
Percentage of Asian employees—
Share of Asian management—
Percentage of Hispanic/Latino employees—
Hispano/Latino Management share—
Percentage of Black employees—
Black Management Share—
Percentage of white employees—
White Management Share—
Adult content
Alcohol
Weapons—
Firearms
Gambling
Military contracts
Human rights concept
Privacy concept—
Occupational health and safety
Catholic
G

Governance (Corporate Governance)

4
Environmental reporting
Stakeholder Engagement
Call Back Policies
Antitrust law

The Eulerpool ESG Scorecard© is the strictly copyrighted intellectual property of Eulerpool Research Systems. Any unauthorized use, imitation, or infringement will be actively pursued and may lead to significant legal consequences. For licenses, collaborations, or usage rights, please contact us directly via our contact form. Contact Form to us.

Sansure Biotech shareholder structure

% Name
0.21679%
The Vanguard Group, Inc.
The Vanguard Group, Inc.
0.09457%
Dimensional Fund Advisors, L.P.
Dimensional Fund Advisors, L.P.
0.01166%
Charles Schwab Investment Management, Inc.
Charles Schwab Investment Management, Inc.
0.00990%
Dimensional Fund Advisors, Ltd.
Dimensional Fund Advisors, Ltd.
0.00811%
State Street Investment Management (US)
State Street Investment Management (US)
0.00773%
Premia Partners Company Limited
Premia Partners Company Limited

Sansure Biotech Beneficial Ownership Filings (SEC 13D/G)

Free Float
51.6%
Float Shares
-
Shares Outstanding
-

Sansure Biotech Executives and Management Board

20 members · avg. age 51 · 15 % women

JZ

Mr. Jian Zhu (48)

Deputy General Manager

2.34 M CNY

Management

PY

Mr. Peng Yin (59)

Senior Vice President, Chief Technology Officer, Deputy General Manager

2.28 M CNY
ZP

Mr. Zhu Peng (48)

Chief Financial Officer, Deputy General Manager, Director · since 2019

1.68 M CNY
KL

Mr. Kai Liu (47)

Deputy General Manager

1.55 M CNY
HW

Mr. Haixiao Wang (46)

Deputy General Manager

1.43 M CNY
JZ

Ms. Jun Zhou (53)

Deputy General Manager

970,400.00 CNY
XX

Ms. Xiaoyan Xiong (41)

Deputy General Manager

621,600.00 CNY

Board of Directors

LD

Mr. Lizhong Dai (55)

Chairman of the Board, General Manager · since 2019

700,600.00 CNY
JL

Mr. Jia Liu (42)

Deputy General Manager, Director · since 2021

557,800.00 CNY
XY

Mr. Xialin Yu (44)

Deputy General Manager, Director · since 2019

439,700.00 CNY
YC

Ms. Ya Cao (73)

Independent Director

80,000.00 CNY
YQ

Mr. Youlin Qiao (69)

Independent Director

80,000.00 CNY
SW

Mr. Shanping Wang (59)

Independent Director

80,000.00 CNY

Sansure Biotech Supply Chain

Sansure Biotech Supply Chain

Correlation: how closely stock prices move together

Same directionNo relationOpposite
2 companies
#NameTrend
1
Tecan Group
Supplier·Life Sciences Tools & Services·CH
0.21
0.60
0.78
0.72
0.39
—
2
Meilleure Health Intl Ind
Customer·Trading Companies & Distributors·HK
-0.33
0.38
0.76
0.70
-0.01
—

Frequently asked questions about Sansure Biotech

Analysts currently set an average price target of 26.42 CNY for the Sansure Biotech stock (median: 26.42 CNY), implying +57.1 % versus the latest price. The consensus is based on 7 analyst ratings.

Sansure Biotech Analyst Price Targets 2026

7 analysts currently rate the Sansure Biotech stock: 6 recommend buying, 1 holding and 0 selling. For 2026, analysts expect Sansure Biotech to generate revenue of 1.82 B CNY and earnings per share of 0.43 CNY.

Sansure Biotech Analyst Price Targets 2026

Converted at the current exchange rate, the Sansure Biotech share trades at 2.16 EUR (16.82 CNY).

No history available for Sansure Biotech.

The expected revenue of Sansure Biotech is 1.82 B CNY. This figure is based on current financial data and reflects the company's business performance.

The expected profit of Sansure Biotech is 250.68 M CNY. The net profit reflects the company's profitability after deducting all expenses.

The price-to-earnings ratio (P/E) of Sansure Biotech is currently 39.35. The P/E ratio compares the current share price to the earnings per share and helps investors assess the valuation of the Sansure Biotech stock.

The price-to-sales ratio (P/S) of Sansure Biotech is currently 5.41. The P/S ratio compares the market capitalization to the annual revenue and serves as a valuation metric for the Sansure Biotech stock.

The Eulerpool Quality Score for Sansure Biotech is 2/10.

The ISIN of Sansure Biotech is CNE1000043J1. The ISIN (International Securities Identification Number) is a globally unique identifier for securities.

The ticker of Sansure Biotech is 688289.SS. The ticker symbol is used to trade Sansure Biotech shares on the stock exchange.

Over the past 12 months, Sansure Biotech paid a dividend of 0.45 CNY . This corresponds to a dividend yield of about 2.68 %. For the coming 12 months, Sansure Biotech is expected to pay a dividend of 0.76 CNY.

The current dividend yield of Sansure Biotech is 2.68 %.

Sansure Biotech pays a dividend, distributed in the months of , , , .

Sansure Biotech paid dividends every year for the past 6 years.

For the upcoming 12 months, dividends amounting to 0.76 CNY are expected. This corresponds to a dividend yield of 4.55 %.

Sansure Biotech is assigned to the 'Health' sector.

In the year 2025, Sansure Biotech distributed 0.45 CNY as dividends.

The dividends of Sansure Biotech are distributed in CNY.

All fundamentals and in-depth analysis of Sansure Biotech

Our stock analysis for Sansure Biotech stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sansure Biotech. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.

Sansure Biotech Stock
Sansure Biotech Revenue→
Sansure Biotech Stock
Sansure Biotech Net Income→
Sansure Biotech Stock
Sansure Biotech P/E→
Sansure Biotech Stock
Sansure Biotech P/S→
Sansure Biotech Stock
Sansure Biotech EBIT→
Sansure Biotech Stock
Sansure Biotech Dividend→
Sansure Biotech Stock
Sansure Biotech Directors Dealings→
Sansure Biotech Stock
Sansure Biotech Stocks→
Sansure Biotech Stock
Sansure Biotech Market capitalization→
Sansure Biotech Stock
Sansure Biotech Debt→
Sansure Biotech Stock
Sansure Biotech Liabilities→
Sansure Biotech Stock
Sansure Biotech Equity→
Sansure Biotech Stock
Sansure Biotech AAQS→
Sansure Biotech Stock
Sansure Biotech Employees→
Sansure Biotech Stock
Sansure Biotech ROE→
Sansure Biotech Stock
Sansure Biotech ROA→
Sansure Biotech Stock
Sansure Biotech ROCE→
Sansure Biotech Stock
Sansure Biotech News→
Sansure Biotech Stock
Sansure Biotech Analyst Price Targets→

Health Stocks

Santen Pharmaceutical CoSanofi IndiaSanthera Pharmaceuticals HoldingSanofi Consumer Healthcare IndiaSANUWAVE HealthSanofi ADRSarana Meditama Metropolitan Tbk PTSanofiSarepta TherapeuticsSanjivani ParanteralSareum HoldingsSanionaAll Stocks A–Z →